Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
We partner with leading pharmaceutical and biotechnology companies to translate innovative science into game-changing breakthroughs and to accelerate global reach of our medicines. We combine our proprietary technology platforms and R&D expertise with the scale, development capabilities, and commercial strength of our partners to deliver innovative treatments to impact patients' lives and in more markets around the world.
OPKO, through ModeX Therapeutics, has partnered with Merck on MDX2201, a next-generation nanoparticle vaccine candidate that targets multiple Epstein-Barr virus (EBV) proteins. Under this exclusive worldwide license and development agreement, ModeX and Merck jointly advanced MDX-2201 into the clinic, and now Merck is responsible for all clinical and regulatory activities, as well as product commercialization.
OPKO is collaborating with Pfizer on the development and commercialization of NGENLA®, a once-weekly long-acting human growth hormone therapy. The partnership leverages Pfizer’s global clinical, regulatory and commercial capabilities alongside OPKO’s endocrine expertise.
OPKO’s ModeX Therapeutics entered into a research collaboration with Regeneron focused on next-generation multispecific antibody technologies. By pairing ModeX’s modular antibody engineering platforms with Regeneron’s biologics capabilities, the partnership aims to create differentiated treatments for oncology and immune-related diseases.
medicalcountermeasures.gov/barda
OPKO’s ModeX Therapeutics has a partnership with BARDA to advance its MSTAR multispecific antibody platform for the prevention and treatment of viral threats, including programs focused on COVID‑19 and influenza. BARDA funding supports the development of these next-generation antibody candidates, which assists in accelerating these programs that are aligned with U.S. pandemic preparedness and public health priorities.
OPKO is collaborating with Entera Bio to combine OPKO’s peptide and protein engineering with Entera’s N-Tab® oral peptide platform to develop first-in-class tablet therapies, including programs in long-acting PTH for hypoparathyroidism and dual GLP-1/glucagon for obesity and metabolic disorders. This partnership is designed to turn injectable peptide medicines into convenient once-daily oral treatments, and has the potential to expand patient access and potentially improve long-term disease management.
We actively seek to collaborate with organizations that share our commitment to delivering next-generation therapies to patients worldwide.
Contact Us